Valion Bio Files $100M Shelf and $5M ATM Program Amid Going Concern
VBIO is trading near its 52-week low of $2.05 (4.9% above the low) on light trading volume (0.1× avg).
Summary
Valion Bio registered a $100M shelf and a $5M ATM program with Rodman & Renshaw, while reiterating going concern doubt and Nasdaq delisting risk.
Key Events · Financing and Capital Events · VBIO
-
$100M Shelf Registration Filed
Valion Bio filed a universal shelf registration statement on October 7, 2026, covering up to $100 million of common stock, preferred stock, debt securities, warrants, subscription rights, and units.
-
$5M ATM Program with Rodman & Renshaw
The company entered into an At-The-Market offering agreement with Rodman & Renshaw LLC to sell up to $5 million of common stock from time to time, with a 3.0% commission to the agent.
-
Going Concern Doubt Reiterated
The prospectus states there is substantial doubt regarding the company's ability to continue as a going concern, and that following this offering the company will still need to raise substantial additional funding.
-
Nasdaq Delisting Risk Disclosed
The prospectus discloses that the company cannot assure the market price of its common stock will remain high enough to comply with Nasdaq's minimum bid price requirement following the 1-for-25 reverse stock split.
Analysis · VBIO · Life Sciences
Valion Bio filed a $100 million universal shelf registration and a $5 million at-the-market offering agreement with Rodman & Renshaw. The prospectus reiterates substantial doubt about the company's ability to continue as a going concern and discloses Nasdaq delisting risk. The ATM program allows the company to sell shares into the market at prevailing prices, providing a potential lifeline but also creating significant dilution overhang for existing shareholders. The company's cash position was only $2.1 million as of the last 10-Q, so this financing capacity is critical for survival.
How filings like this one have moved
In the 30 days to Oct 8, 2026, 36.4% of the 1096 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VBIO was trading at $2.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9M. The 52-week trading range was $2.05 to $78.75. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.